{name}
{subtitle}
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
city
~61 mi. (Billings, Montana, +89 more cities)
facility
St. Vincent Frontier Cancer Center
biomarker
ER Positive, +1 more biomarker
drug
giredestrant, +1 more drug
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
city
~61 mi. (Billings, Montana, +523 more cities)
facility
Billings Clinic Cancer Center
drug
cabozantinib, +2 more drugs
drug type
immunotherapy, +1 more type
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~61 mi. (Billings, Montana, +226 more cities)
facility
St. Vincent Frontier Cancer Center ( Site 0016)
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
city
~61 mi. (Billings, Montana, +454 more cities)
facility
Billings Clinic Cancer Center
drug
brentuximab vedotin, +7 more drugs
drug type
chemotherapy, +3 more types
A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
city
~61 mi. (Billings, Montana, +233 more cities)
facility
Billings Clinic Cancer Center
drug
degarelix, +4 more drugs
drug type
hormone therapy, +1 more type
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
city
~61 mi. (Billings, Montana, +262 more cities)
facility
St. Vincent Frontier Cancer Center
biomarker
ER Positive, +1 more biomarker
drug
giredestrant, +2 more drugs
drug type
hormone therapy, +1 more type
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
city
~61 mi. (Billings, Montana, +127 more cities)
facility
St. Vincent Frontier Cancer Center, +1 more facility
drug
cetuximab, +3 more drugs
drug type
chemotherapy, +1 more type
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
city
~61 mi. (Billings, Montana, +207 more cities)
facility
St. Vincent Frontier Cancer Center ( Site 0033)
biomarker
ER Positive, +1 more biomarker
drug
cyclophosphamide, +6 more drugs
drug type
chemotherapy, +3 more types